Technology | Drug-Eluting Balloons | September 26, 2016

FDA Approves Six-Month Primary End Point for Lutonix Below-the-Knee Drug Coated Balloon

Clinical trial evaluating Lutonix 014 DCB for stenosis, BTK artery occlusion with cumulative lesion length up to 320 mm with reference vessel diameters of 2-4 mm

Bard, Lutonix 014 DCB, drug-coated balloon, six-month endpoint, FDA IDE trial

September 26, 2016 — C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) supplemental application to modify the primary endpoint to a six-month time point for the Lutonix 014 Drug Coated Balloon PTA Catheter (DCB). The Lutonix 014 device is currently the only DCB in an IDE clinical trial in the United States for treatment of arteries below the knee (BTK).

The clinical trial is evaluating the device when used for the treatment of stenosis or occlusion of native BTK arteries with a cumulative lesion length up to 320 mm with reference vessel diameters of 2 to 4 mm. Currently, the study has enrolled approximately 340 patients, of which 69 percent are diabetic, 33 percent are female and 95 percent have critical limb ischemia (CLI). The primary safety end point in the study is freedom from major adverse limb event or post-operative death at 30 days and the primary efficacy end point is a composite of limb salvage and primary patency at 6 months. An independent data monitoring committee, which is chartered to review patient safety for the study, has met for the tenth time and unanimously recommended continuation of the study with no modifications.

Similar to the Lutonix 035 DCB, the first drug-coated balloon approved in the U.S., the Lutonix 014 DCB is an angioplasty balloon that is coated with a low dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD). The Lutonix 035 DCB is also the only DCB being evaluated in an IDE trial for the treatment of dysfunctional arteriovenous fistulae located in the upper extremity.

PAD is estimated to be present in 3 percent of people in the age range of 40 to 59 years and in 20 percent of people over 70 years of age. The majority of patients undergoing BTK interventions suffer from CLI, with high cardiovascular risk and often significant medical co-morbidities. CLI is typically defined as limb pain that occurs at rest (Rutherford Category 4), or impending limb loss that is caused by severely compromised blood flow to the affected extremity leading to non-healing ulcers (Rutherford Category 5 and 6).

“Below-the-knee PAD is a challenging disease in a patient group that is currently under served. Patients often have to undergo frequent reinterventions following initial treatment. Regular balloon angioplasty is the primary catheter-based treatment option available today” said Michael R. Jaff, M.D., medical director of VasCore, the vascular ultrasound core laboratory used in the Lutonix BTK trial.

“A significant number of patients with BTK disease are at risk of limb loss and would be expected to benefit from alternative treatment options. The Lutonix 014 DCB could offer physicians an opportunity to change the treatment paradigm for patients by providing a safe and effective method to deliver paclitaxel directly to stenosed BTK vessels,” said Jihad Mustapha, M.D., Lutonix BTK principal investigator.

The Lutonix 014 DCB has been available commercially in Europe since 2013 and is available in most geographies outside the United States.

For more information: www.crbard.com

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init